Genetic Polymorphism in <i>ATG16L1</i> Gene Influences the Response to Adalimumab in Crohn’s Disease Patients

Abstract

Our results suggest ADA response in CD patients is genetically predisposed by SNPs in CD risk genes and suggest ATG16L1 as most promising candidate gene for drug response in ADA treatment. Original submitted 24 September 2014; Revision submitted 1 December 2014.